IMA 970A

Drug Profile

IMA 970A

Alternative Names: Cancer Vaccine - HEPAVAC; Hepatocellular carcinoma vaccine - HapaVaC; HepaVac-101 vaccine; IMA 970 A

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fondazione IRCCS Istituto Nazionale dei Tumori; immatics biotechnologies GmbH; University of Insurbia; University of Tubingen
  • Developer CureVac; immatics biotechnologies GmbH; National Cancer Institute, Naples
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatocellular carcinoma

Most Recent Events

  • 18 Sep 2017 Phase-I/II clinical trials in Hepatocellular carcinoma (Second-line therapy or greater, Combination therapy) in Spain, Germany (Intradermal) (NCT03203005)
  • 05 Jul 2017 Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute, Naples), Immatics Biotechnologies and CureVac plan a first-in-man phase I/II HepaVac-101 trial for Hepatocellular carcinoma (Combination therapy) in Belgium, France, Germany, Italy, Spain and United Kingdom (NCT03203005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top